Navigation Links
New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
Date:9/20/2012

ract # 494P
Date: Monday, October 1
Time: 13:00 – 14:00 PM CESTImpact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after chemotherapy (ctx) and erlotinib (E) or gefitinib (G) – A single center experience

 

Jens Koehler,

MD

ESMO Abstract # 1339
Publication OnlyCombination Afatinib* and Nintedanib*Phase I study of afatinib (BIBW 2992), an ErbB family blocker plus nintedanib (BIBF 1120), a triple angiokinase inhibitor, in patients (pts) with advanced solid tumours

Jean-Charles Soria,

MD, PhD

ESMO Abstract # 446PD
Date: Sunday, September 30
Time: 13:00 – 14:00 PM CESTNintedanib*Phase I study of nintedanib (BIBF 1120) in European patients with advanced hepatocellular carcinoma

Daniel Palmer

ESMO Abstract # 740P
Date: Sunday, September 30
Time: 13:00 – 14:00 PM CESTEarly data from a phase I study of nintedanib (BIBF 1120) in Asian patients with advanced hepatocellular carcinoma

Chia-Jui Yen,

MD, PhD

ESMO Abstract # 744P
Date: Sunday, September 30
Time: 13:00 – 14:00 PM CEST*Afatinib and nintedanib are investigational compounds; their efficacy and safety have not been established.About Boehringer Ingelheim in OncologyBuilding on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

The current focus of l
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
2. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
3. 500 Oncology Providers Sign Up for Navigating Cancers Patient Engagement Portal
4. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
5. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
6. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
7. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
8. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
9. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
10. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2
... , FLORHAM PARK, N.J., June 1 Today, BASF filed ... District of Delaware against DuPont (E. l. du Pont de ... confers tolerance to a key class of herbicides. Specifically, DuPont,s ... an important genetic component that enables successful tolerance toward an ...
... NOVATO, Calif., June 1 Raptor Pharmaceuticals Corp. ... today announced that it has dosed the first ... in collaboration with the University of California, ... delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic ...
... - Results Presented at American Society of Clinical Oncology ... with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory ... Mersana Therapeutics presented preliminary results of a Phase ... in a poster session at the 2009 Annual Meeting ...
Cached Biology Technology:BASF Sues DuPont for Patent Infringement 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3
(Date:7/10/2014)... in New Mexico, nearly every public golf course is ... potable water supplies. Across the U.S. Southwest as a ... treated effluent. Reusing the effluent increases the sustainability of ... alike fertilize their lawns during the growing season. The ... State University turfgrass expert has a new vision for ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
(Date:7/10/2014)... SPRINGS, Florida , July 1, 2014 ... wallets pave way for convenience and improved security: NXT-ID, Inc. ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) ... is pleased to announce that the second series of 30 ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5
... 22, 2011 - The Vilcek Foundation is pleased to announce ... of foreign-born scientists and artists. The sixth annual ... sustained record of innovation and achievement, is awarded to Dutch-born ... of the laboratory of Cell Biology and Genetics at Rockefeller ...
... (BRONX, NY) Ertuğrul zbudak, Ph.D. , assistant ... of Medicine of Yeshiva University, has won a ... his research into the genetic causes of vertebral malformations that ... adult diseases, including scoliosis, disfigurement, and back and neck pain. ...
... 2011) -- A lab at Rice University has stepped forward ... that preserves their unique properties -- and adds more. ... functionalities to remain in close contact with single-walled carbon nanotubes ... separation is critical to manufacturers who want to spin fiber ...
Cached Biology News:Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 2Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science 3Albert Einstein College of Medicine geneticist wins Sloan Research Fellowship 2Metallic molecules to nanotubes: Spread out! 2Metallic molecules to nanotubes: Spread out! 3
UBN-1 (C-20)...
P2A4...
pETDuet-1 is designed for the coexpression of two target genes....
... Cl- Cotransporter-1 (KCC1). The ... sequence homology with other ... The immunogen sequence is ... mouse, porcine and rabbit. ...
Biology Products: